RxDoctor Payments Data

Daniel Dulas, MD

Cardiovascular Disease · Minneapolis, MNNPI 1285672626

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,322 of the $2,748 with a category attached, or 84.5%. 19 manufacturers reported payments, led by Cardiovascular Systems Inc. at 38.9% of the total. Reporting peaked in 2020 at $1,052 and has fallen 80.8% since, to $202 in 2025.

$2,748in general payments, 2019–2025

Across 68 payments — averaging $40.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$1K
  • Abbott$299
  • Abiomed$277
  • Philips North America LLC$240
  • Surmodics, Inc.$146
  • Cvrx, Inc.$135
  • plus $581 from 13 others
$629,573in research payments, 2019–2025

Across 176 payments — averaging $3577.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cardiovascular Systems Inc.$474K
  • Abbott$86K
  • Boston Scientific$47K
  • Bayer$12K
  • Medtronic$10K

What the payments were for

  • Travel & lodging$42615%
  • Food & beverage$2,32285%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,748 in reported general payments places this provider in the 60th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$71,622
Medicare patients
384
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$22,569
XareltoRivaroxaban13$15,861
Atorvastatin Calcium146$2,034
Metoprolol Succinate142$1,900
ClopidogrelClopidogrel Bisulfate166$1,676
Isosorbide Mononitrate ErIsosorbide Mononitrate76$1,625
Rosuvastatin Calcium87$1,122
Lisinopril87$943
Carvedilol45$736
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$718
Losartan Potassium29$355
Valsartan14$352
Metoprolol Tartrate69$344
Warfarin Sodium23$296
Furosemide39$268

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →